Ownership Submission
FORM 4
|
Check this box if no longer subject to Section 16, Form 4 or Form 5 obligations may continue. See Instruction 1(b).
|
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
|
OMB APPROVAL
|
OMB Number:3235-0287Expires:January 31, 2005Estimated average burden hours per response...0.5
|
|
1. Name and Address of Reporting Person *
|
BARRY JAMES
|
|
2. Issuer Name and Ticker or Trading Symbol
BIO-RAD LABORATORIES, INC. [BIO BIOB]
|
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
_____ Director
|
_____ 10% Owner
|
_____ Officer (give title below)
|
_____ Other (specify below)
|
EVP, President, LSG /
|
|
(Last)
|
(First)
|
(Middle)
|
C/O BIO-RAD LABORATORIES, INC. , 1000 ALFRED NOBEL DRIVE
|
|
3. Date of Earliest Transaction (Month/Day/Year)
|
(Street)
|
HERCULES
|
CA
|
94547
|
|
4. If Amendment, Date Original Filed(Month/Day/Year)
|
6. Individual or Join/Group Filing(Check Applicable Line)
_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
|
|
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
|
|
1.Title of Security
|
2. Transaction Date (Month/Day/Year)
|
2A. Deemed Execution Date, if any (Month/Day/Year)
|
3. Transaction Code
|
4. Securities Acquired (A) or Disposed of (D)
|
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
|
6. Ownership Form: Direct (D) or Indirect (I)
|
7. Nature of Indirect Beneficial Ownership
|
Code
|
V
|
Amount
|
(A) or (D)
|
Price
|
|
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
|
2. Conversion or Exercise Price of Derivative Security
|
3. Transaction Date (Month/Day/Year)
|
3A. Deemed Execution Date, if any (Month/Day/Year)
|
4. Transaction Code
|
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
|
6. Date Exercisable and Expiration Date
|
7. Title and Amount of Securities Underlying Derivative Security
|
8. Price of Derivative Security
|
9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s)
|
10. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
|
11. Nature of Indirect Beneficial Ownership
|
Code
|
V
|
(A)
|
(D)
|
Date Exercisable
|
Expriation Date
|
Title
|
Amount or Number of Shares
|
Reporting Owners
Reporting Owner Name / Address
|
Relationships
|
Director
|
10% Owner
|
Officer
|
Other
|
BARRY JAMES
C/O BIO-RAD LABORATORIES, INC.
1000 ALFRED NOBEL DRIVE
HERCULES, CA94547
|
|
|
EVP, President, LSG
|
|
Signatures
/s/ James Barry
|
2024-09-04
|
**Signature of Reporting Person
|
Date
|
Explanation of Responses:
(*)
|
If the form is filed by more than one reporting person, see Instruction 5(b)(v).
|
(**)
|
Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
|
(1)
|
Shares of Class A common stock acquired on the vesting of restricted stock units.
|
(2)
|
Includes 45.6820 shares acquired under the Bio-Rad Employee Stock Purchase Plan on 06/30/2024.
|
(3)
|
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $330.40 to $330.63, inclusive. The reporting person undertakes to provide to Bio-Rad Laboratories, Inc., any security holder of Bio-Rad Laboratories, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
|
(4)
|
Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock.
|
(5)
|
On September 1, 2023, the reporting person was granted 1,002 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date.
|
(6)
|
On September 1, 2022, the reporting person was granted 694 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date.
|
(7)
|
On September 1, 2021, the reporting person was granted 709 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date.
|
(8)
|
On September 2, 2020, the reporting person was granted 1,059 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date.
|
(9)
|
On September 3, 2019, the reporting person was granted 1,083 restricted stock units, vesting in five equal annual installments beginning on the first anniversary of the grant date.
|
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient,
See Instruction 6 for procedure.Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.